LLY vs MRK — Key Metrics
| Metric | LLY (ELI LILLY & CO) | MRK (MERCK & CO INC) |
|---|---|---|
| Price | 1382.75 | 137.78 |
| Market Cap | 1.3 Trillion | 339.66 Billion |
| P/E (TTM) | 44.82 | 137.78 |
| P/B (Quarterly) | 32.09 | 8.257 |
| P/S (TTM) | 15.04 | 5.04 |
| Net Profit Margin (TTM) | 31.9 | 3.6 |
| Gross Margin (TTM) | 83.6 | 71.8 |
| ROE (TTM) | 83.6 | 5.3 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Underperform
Greatly Outperform
Recommendation Summary
Stock LLY is projected to underperform the market, stock MRK is projected to greatly outperform the market. Upfront Recommendation: MRK.
Financial Metrics
| LLY | Metrics | MRK |
|---|---|---|
| $1,382.75 | Price | $137.78 |
| — | Market Capitalization | — |
| 44.82 | Price to Earnings Ratio | 137.78 |
| 15.04 | Price to Sales | 5.04 |
| 66.16 | Price to FCF Ratio | 23.03 |
| 17.99 | Price to Gross Profit | 7.03 |
| 84.59 | Price to R&D | 11.04 |
| 19.93 | Price to Current Assets | 8.72 |
LLY vs MRK at a glance
ELI Lilly & CO (LLY) and Merck & CO INC (MRK) are both Drug Manufacturers - General companies in the Healthcare sector. LLY is the larger, at $1.3 trillion in market value against $339.7 billion for MRK, about 3.8 times the size.
On trailing-twelve-month figures, LLY trades at 44.8 times trailing earnings and MRK at 137.8; net profit margins are 31.9% and 3.6%.
The Upfront Investment model currently rates LLY Underperform and MRK Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.